Jong Chul Park

1.8k total citations
59 papers, 727 citations indexed

About

Jong Chul Park is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Jong Chul Park has authored 59 papers receiving a total of 727 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in Jong Chul Park's work include Cancer Immunotherapy and Biomarkers (22 papers), Prostate Cancer Treatment and Research (10 papers) and CAR-T cell therapy research (9 papers). Jong Chul Park is often cited by papers focused on Cancer Immunotherapy and Biomarkers (22 papers), Prostate Cancer Treatment and Research (10 papers) and CAR-T cell therapy research (9 papers). Jong Chul Park collaborates with scholars based in United States, South Korea and Canada. Jong Chul Park's co-authors include Csaba P. Kövesdy, Kamyar Kalantar‐Zadeh, Mario A. Eisenberger, Emmanuel S. Antonarakis, Srinivas Vinod Saladi, Yong K. Park, Fawaz Almutairi, William B. Isaacs, Tamara L. Lotan and Colin C. Pritchard and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jong Chul Park

56 papers receiving 716 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jong Chul Park United States 14 327 278 105 105 92 59 727
Lukas Käsmann Germany 17 483 1.5× 510 1.8× 151 1.4× 100 1.0× 68 0.7× 99 977
Dae Sik Yang South Korea 16 204 0.6× 190 0.7× 201 1.9× 87 0.8× 89 1.0× 85 806
Laura Schirosi Italy 15 349 1.1× 244 0.9× 85 0.8× 113 1.1× 51 0.6× 30 755
Abhineet Uppal United States 15 332 1.0× 323 1.2× 168 1.6× 216 2.1× 36 0.4× 66 907
Gerd Wunderlich Germany 20 173 0.5× 270 1.0× 74 0.7× 127 1.2× 139 1.5× 53 852
Chai Hong Rim South Korea 18 290 0.9× 370 1.3× 367 3.5× 103 1.0× 57 0.6× 96 1.2k
Charles Dariane France 16 283 0.9× 525 1.9× 185 1.8× 168 1.6× 21 0.2× 97 867
Jean‐Philippe Vuillez France 15 210 0.6× 142 0.5× 88 0.8× 121 1.2× 183 2.0× 39 907
Toshifumi Kurahashi Japan 17 272 0.8× 476 1.7× 215 2.0× 228 2.2× 30 0.3× 50 868

Countries citing papers authored by Jong Chul Park

Since Specialization
Citations

This map shows the geographic impact of Jong Chul Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jong Chul Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jong Chul Park more than expected).

Fields of papers citing papers by Jong Chul Park

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jong Chul Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jong Chul Park. The network helps show where Jong Chul Park may publish in the future.

Co-authorship network of co-authors of Jong Chul Park

This figure shows the co-authorship network connecting the top 25 collaborators of Jong Chul Park. A scholar is included among the top collaborators of Jong Chul Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jong Chul Park. Jong Chul Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bryan, Michael, Ross D. Merkin, Thomas J. Roberts, et al.. (2025). Spatial characterization of tertiary lymphoid structures as predictive biomarkers for immune checkpoint blockade in head and neck squamous cell carcinoma. OncoImmunology. 14(1). 2466308–2466308. 1 indexed citations
2.
Qin, Tingting, Austin K. Mattox, Jean S. Campbell, et al.. (2025). Epigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge. Journal of Clinical Investigation. 135(6). 5 indexed citations
3.
Merkin, Ross D., Michael Bryan, Thomas J. Roberts, et al.. (2025). Personalized circulating tumor DNA dynamics inform survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancer. npj Precision Oncology. 9(1). 298–298. 1 indexed citations
4.
Park, Jong Chul, Jong Seok Ahn, Ross D. Merkin, et al.. (2025). Correlates of Cetuximab Efficacy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Previously Treated With Immunotherapy. JCO Precision Oncology. 9(9). e2400741–e2400741. 1 indexed citations
5.
Weaver, Alice N., Wade T. Iams, Jong Chul Park, et al.. (2024). Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration. Molecular Carcinogenesis. 63(8). 1421–1428. 2 indexed citations
6.
7.
Park, Jong Chul, et al.. (2024). Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer. JCO Precision Oncology. 8(8). e2400179–e2400179. 1 indexed citations
8.
Coté, Gregory M., Bose Kochupurakkal, T. Khanh, et al.. (2024). A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors. Clinical Cancer Research. 31(1). 35–44. 4 indexed citations
9.
Russell, Marika D., Amr H. Abdelhamid Ahmed, Zipei Feng, et al.. (2024). Recovery of Recurrent Laryngeal Nerve Function With Neoadjuvant Treatment: Neural Characterization. The Laryngoscope. 134(7). 3415–3419. 1 indexed citations
10.
Colevas, A. Dimitrios, Christine H. Chung, Douglas R. Adkins, et al.. (2024). A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).. Journal of Clinical Oncology. 42(16_suppl). 6004–6004. 8 indexed citations
11.
Park, Jong Chul, David Berz, Manish Sharma, et al.. (2023). 742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors. SHILAP Revista de lepidopterología. A836–A837. 2 indexed citations
12.
Rizvi, Naiyer A., Foluso O. Ademuyiwa, Z. Alexander Cao, et al.. (2023). Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy. Journal for ImmunoTherapy of Cancer. 11(3). e005920–e005920. 24 indexed citations
13.
Marshall, Catherine H., Wei Fu, Hao Wang, et al.. (2021). Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research. 27(6). 1623–1630. 39 indexed citations
14.
Hanna, Glenn J., Eleni M. Rettig, Jong Chul Park, et al.. (2020). Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. Oral Oncology. 112. 105087–105087. 6 indexed citations
15.
Park, Jong Chul, et al.. (2020). Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes. Oral Oncology. 111. 105024–105024. 11 indexed citations
16.
Park, Jong Chul, Ting Martin, Lisa M. Rooper, et al.. (2018). Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor‐2 high expressing salivary duct carcinomas. Head & Neck. 40(12). E100–E106. 21 indexed citations
17.
Park, Jong Chul, et al.. (2018). Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer. Epidemiology and Health. 40. e2018040–e2018040. 6 indexed citations
18.
Guedes, Liana B., Emmanuel S. Antonarakis, Michael T. Schweizer, et al.. (2017). MSH2 Loss in Primary Prostate Cancer. Clinical Cancer Research. 23(22). 6863–6874. 112 indexed citations
19.
Kövesdy, Csaba P., Jong Chul Park, & Kamyar Kalantar‐Zadeh. (2010). Glycemic Control and Burnt‐Out Diabetes in ESRD. Seminars in Dialysis. 23(2). 148–156. 87 indexed citations
20.
Hur, Nam Hwi, et al.. (1994). New members in the family of Hg and Tl based superconductors Hg1−xTlxBa2(Ca0.86Sr0.14)2Cu3O8+δ. Physica C Superconductivity. 234(1-2). 19–23. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lukas Käsmann Breakdown of academic impact, for papers by Dae Sik Yang Breakdown of academic impact, for papers by Laura Schirosi Breakdown of academic impact, for papers by Abhineet Uppal Breakdown of academic impact, for papers by Gerd Wunderlich Breakdown of academic impact, for papers by Chai Hong Rim Breakdown of academic impact, for papers by Charles Dariane Breakdown of academic impact, for papers by Jean‐Philippe Vuillez Breakdown of academic impact, for papers by Toshifumi Kurahashi
Rankless by CCL
2026